Updated news

jfkonecn · Sep 19, 2024 · 2f155f0 · 2f155f0
1 parent 3931566
commit 2f155f0
Showing 1 changed file with 33 additions and 4 deletions.
diff --git a/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx b/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx
@@ -305,7 +305,36 @@ export const NEWS_BY_DATE: { [date: string]: NewsData } = {
             'Neuroblastoma',
             'Lorlatinib',
             <WithSeparator separator={EVIDENCE_COLUMN_SEPARATOR}>
-              <PMIDLink pmids="38410486,  37012551, 26554404, 38032104, 27483357" />
+              <PMIDLink pmids="37012551, 26554404, 38032104, 27483357" />
+            </WithSeparator>,
+          ],
+          [
+            '3A',
+            'MET',
+            <WithSeparator separator={', '}>
+              {getAlternativeAllelesPageLinks('MET', 'H1094Y')}
+              {getAlternativeAllelesPageLinks('MET', 'F1200I')}
+            </WithSeparator>,
+            'Non-Small Cell Lung Cancer',
+            'Elzovantinib',
+            <WithSeparator separator={EVIDENCE_COLUMN_SEPARATOR}>
+              <PMIDLink pmids="38564707" />
+            </WithSeparator>,
+          ],
+          [
+            '4',
+            'MET',
+            <WithSeparator separator={', '}>
+              {getAlternativeAllelesPageLinks('MET', 'N1100S')}
+              {getAlternativeAllelesPageLinks('MET', 'V1092I')}
+              {getAlternativeAllelesPageLinks('MET', 'H1106D')}
+              {getAlternativeAllelesPageLinks('MET', 'R1170Q')}
+              {getAlternativeAllelesPageLinks('MET', 'M1250T')}
+            </WithSeparator>,
+            'Non-Small Cell Lung Cancer',
+            'Type Ib MET Inhibitors: Elzovantinib, Capmatinib, Tepotinib',
+            <WithSeparator separator={EVIDENCE_COLUMN_SEPARATOR}>
+              <PMIDLink pmids="38564707" />
             </WithSeparator>,
           ],
         ],
@@ -319,8 +348,8 @@ export const NEWS_BY_DATE: { [date: string]: NewsData } = {
             'EGFR',
             'Exon 19 in-frame deletions, L858R',
             'Non-Small Cell Lung Cancer',
-            'Afatinib, Dacomitinib, Erlotinib, Erlotinib + Ramucirumab, Gefitinib, Osimertinib, Osimertinib + Chemotherapy (Level 1); Amivantamab + Chemotherapy (Level 2); Amivantamab + Lazertinib, Patritumab Deruxtecan (Level 3A',
-            'Amivantamab + Lazertinib (Level 1)',
+            'Afatinib, Dacomitinib, Erlotinib, Erlotinib + Ramucirumab, Gefitinib, Osimertinib, Osimertinib + Chemotherapy (Level 1); Amivantamab + Chemotherapy (Level 2); Amivantamab + Lazertinib, Patritumab Deruxtecan (Level 3A)',
+            'Amivantamab + Lazertinib (Level 1; Promoted from Level 3A)',
             <WithSeparator separator={EVIDENCE_COLUMN_SEPARATOR}>
               <FdaApprovalLink
                 approval="Amivantamab + Lazertinib"
@@ -332,7 +361,7 @@ export const NEWS_BY_DATE: { [date: string]: NewsData } = {
         ],
       },
     ],
-    newlyAddedGenes: ['ABCB1', 'ADGRA2', 'ELL2', 'XPA'],
+    newlyAddedGenes: ['ABCB1', 'ACVR2A', 'ADGRA2', 'BCL2L2', 'ELL2', 'XPA'],
   },
   '08152024': {
     changedAnnotations: [